Introduction
Recombinant Human CXCL10/IP-10 Protein, also known as interferon gamma-induced protein 10 (IP-10), is a chemokine protein that plays a crucial role in the immune system. It is produced by various cell types, including monocytes, endothelial cells, fibroblasts, and keratinocytes, in response to interferon-gamma (IFN-γ) stimulation. This protein is involved in a range of biological processes, including inflammation, immune response, and cell migration, making it a valuable tool in both research and clinical applications.
Structure of Recombinant Human CXCL10/IP-10 Protein
The recombinant form of CXCL10/IP-10 is a 77 amino acid protein with a molecular weight of approximately 8.5 kDa. It is composed of a single chain of amino acids with a conserved N-terminal sequence and a highly variable C-terminal sequence. The protein contains four cysteine residues that form two disulfide bonds, which are essential for maintaining its tertiary structure and biological activity.
The three-dimensional structure of CXCL10/IP-10 consists of a three-stranded β-sheet and an α-helix, which are connected by two loops. The N-terminal region contains the first two β-strands, while the C-terminal region contains the third β-strand and the α-helix. This unique structure allows CXCL10/IP-10 to interact with its receptors and exert its biological functions.
Activity of Recombinant Human CXCL10/IP-10 Protein
CXCL10/IP-10 is a potent chemoattractant for immune cells, particularly T cells, natural killer (NK) cells, and monocytes. It exerts its activity by binding to its receptors, CXCR3 and CXCR3B, which are expressed on the surface of these cells. This binding triggers a signaling cascade that leads to the activation of various immune cell functions, such as cell migration, adhesion, and cytokine production.
In addition to its chemoattractant activity, CXCL10/IP-10 also has anti-angiogenic properties. It inhibits the growth of new blood vessels by suppressing the proliferation and migration of endothelial cells, which is important in controlling inflammation and tumor growth.
Applications of Recombinant Human CXCL10/IP-10 Protein
Recombinant Human CXCL10/IP-10 Protein has various applications in both research and clinical settings. In research, it is used as a tool to study the role of CXCL10/IP-10 in various biological processes, including immune response, inflammation, and angiogenesis. It can also be used to investigate the signaling pathways involved in CXCL10/IP-10-mediated functions.
In clinical applications, CXCL10/IP-10 has been shown to be a potential biomarker for various diseases, such as autoimmune disorders, viral infections, and cancer. Elevated levels of CXCL10/IP-10 have been observed in patients with rheumatoid arthritis, multiple sclerosis, hepatitis, and various types of cancer. This makes CXCL10/IP-10 a promising diagnostic and prognostic marker for these diseases.
Furthermore, recombinant CXCL10/IP-10 has been used in clinical trials as a therapeutic agent for the treatment of various diseases. It has been shown to have anti-tumor activity in preclinical studies, and clinical trials are currently underway to evaluate its efficacy in cancer treatment. In addition, CXCL10/IP-10 has been investigated as a potential therapeutic for autoimmune disorders and viral infections, with promising results.
Conclusion
Recombinant Human CXCL10/IP-10 Protein is a versatile chemokine that plays a crucial role in the immune system. Its unique structure and activity make it a valuable tool in research and a potential biomarker and therapeutic agent in clinical applications. With ongoing research and clinical trials, the full potential
There are no reviews yet.